Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
Clinical trial NCT02719015 · WITHDRAWN
Trial details
- NCT number
- NCT02719015
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-01
- Primary completion
- 2022-03-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.